Market Place
Sourcing Support
FDA Accepts Celcuity`s Gedatolisib for HR+/HER2- PIK3CA-WT Cancer
20 Jan 2026 //
GLOBENEWSWIRE
Celcuity Presents PIK3CA WT VIKTORIA-1 Results at 2025 SABCS
11 Dec 2025 //
GLOBENEWSWIRE
Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025
26 Nov 2025 //
GLOBENEWSWIRE
Celcuity Submits NDA for Gedatolisib in HR+/HER2- Breast Cancer
17 Nov 2025 //
GLOBENEWSWIRE
Celcuity Reports Q3 2025 Financial Results & Corporate Update
12 Nov 2025 //
GLOBENEWSWIRE
Celcuity Updates Phase 1 Data On Gedatolisib Plus Darolutamide
18 Oct 2025 //
GLOBENEWSWIRE
Celcuity Updates PIK3CA Mutated Cohort In VIKTORIA-1 Trial
18 Oct 2025 //
GLOBENEWSWIRE
Celcuity To Unveil Phase 3 Viktoria-1 Trial Results At 2025 Esmo
22 Sep 2025 //
GLOBENEWSWIRE
Celcuity`s New Gedatolisib Patent Extends Exclusivity to 2042
14 Jul 2025 //
GLOBENEWSWIRE
Celcuity Presents Gedatolisib Survival Data at SABCS 2024
11 Dec 2024 //
GLOBENEWSWIRE
Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing
30 May 2024 //
GLOBENEWSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib
22 Feb 2024 //
GLOBENEWSWIRE
Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer
06 Dec 2023 //
GLOBENEWSWIRE
Celcuity to Present Preclinical Data for Gedatolisib
01 Dec 2023 //
GLOBENEWSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib
09 Dec 2022 //
ACCESSWIRE
Celcuity Announces First Patient Dosed in PIII VIKTORIA-1 Trial of Gedatolisib
07 Dec 2022 //
ACCESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.